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The presence of the Philadelphia chromosome andBCR/ABL1 fusion, combined with an elevated leuko-cyte count and other less specific clinical and hemato-
logical features, defines chronic myeloid leukemia (CML). In
the last two decades, tyrosine kinase inhibitors (TKIs) have
revolutionized CML treatment.1 The challenge now is to erad-
icate the disease. Three main crucial questions remain: first,
which TKI should be used as first-line therapy, given the
‘embarrassment of riches’ with regard to the choices; second,
who should discontinue TKI, and when; and last, what about
the future?
Which TKI should be chosen as first–line therapy?
Being the first TKI to receive approval for the treatment of
CML, imatinib has definitely changed the natural history of
this disease. The recently published update of the IRIS trial
shows that patients assigned to receive imatinib 400 mg per
day have an estimated overall survival (OS) rate of 83.3% at
10 years, almost matching that of a control population with-
out CML.2 However only approximately half of the original-
ly enrolled patients (48.3%) completed study treatment with
imatinib with such a long follow-up; discontinuation
occurred in 15.9% of patients because of insufficient thera-
peutic effect and in 6.9% of cases because of adverse events;
in addition, during study treatment 6.9% of the patients pro-
gressed to accelerated or blast crisis. Most of the patients
who discontinued imatinib and who were not transplanted
were subsequently moved to alternate treatment.
As it is well known that the final outcome in terms of OS
and progression free survival (PFS) of CML patients corre-
lates to the depth and rapidity of the cytogenetic and molec-
ular responses achieved, the  European LeukemiaNet (ELN)
recommendations have established molecular and cytoge-
netic parameters to be achieved by patients at specific time-
points after the start of TKI therapy. If these parameters are
not achieved, a switch of TKI, if possible, is recommended.3
The second-generation TKI dasatinib, initially approved in
2006 as second-line treatment for patients resistant or intol-
erant to imatinib,4 was finally approved as a first-line thera-
py in 2010 following the results of the phase 3 DASISION
study.5 In this study the cumulative one-year major molecu-
lar response (MMR; 0.1% BCR-ABL) rate was 46% for dasa-
tinib and 28% for imatinib. At five years, the cumulative
MMR rate remained higher with dasatinib (76%) than with
imatinib (64%). Whereas only 16% of the patients treated
with dasatinib failed to achieve, at three months, early
molecular response (EMR; a threshold of BCR-ABL is  seen
to correlate with OS and PFS) this percentage was 36% with
imatinib.6 Finally, very deep molecular responses (DMR;
MR4, MR4.5), which were of greater interest due to the
understandable desire of many patients to achieve treatment
free remission (TFR), were definitely higher with dasatinib
than with imatinib (MR4.5 42% vs. 32%). However, the
five-year OS and PFS rates for dasatinib were 91% and 85%,
respectively, and did not differ from that observed with ima-
tinib; in addition, dasatinib therapy was associated with risk
of developing pleural effusion.6
Nilotinib is a second-generation TKI which was accepted
in 2007 for the treatment of CML resistant or intolerant to
imatinib.7 It was approved for first-line treatment of chronic
phase CML in 2010, following the positive results from the
phase 3 ENESTnd study.8 In the aforementioned trial, after a
minimum follow-up of five years, the rates of MMR and
MR4.5 continue to be significantly higher in both nilotinib
arms versus the imatinib arm (MMR: 77 and 77.2% versus
60%; MR4.5: 53.5 and 52.3% versus 31.4%), with more than
half of the nilotinib-treated patients achieving MR4.5 by five
years. Comparing nilotinib 300 mg twice daily (BID) with
imatinib 400 mg daily, several differences emerge at the
three month landmark on therapy: 91% of nilotinib-treated
versus 67% of imatinib-treated patients achieved BCR-ABL
transcript levels ≤10% EMR; 56% of nilotinib versus only
16% of imatinib patients achieved BCR-ABL transcript levels
≤1%. Although rates of freedom from progression to accel-
erated phase and blastic phase (AP/BC) remain statistically
higher in the nilotinib-treated patients (96.3% and 97.8% for
nilotinib versus 92.1% for imatinib), the estimated rate of OS
is statistically superior only for nilotinib 400 mg BID arm
patients compared to imatinib. Importantly, the occurrence
of metabolic changes such as worsening glycemic control
and lipid increase as well as cardiovascular events (CVEs)
increasing over time with follow-up has been more fre-
quently observed in both nilotinib arms. Although mainly
observed in patients with an increased Framingham risk
score, predictive of CVEs,9 increased attention to cardiovas-
cular risk assessment and comorbidities for all CML patients
is warranted.
Frontline use of bosutinib was initially investigated in the
phase 3 BELA trial, but this study failed to meet its primary
endpoint of complete cytogenetic response (CCyR) at 12
months.10 Bosutinib has been subsequently re-investigated
versus imatinib for chronic phase CML patients at a dosage
of 400mg per day in the phase 3 BFORE trial. In this study,
the proportion of patients who achieved MMR at 12 months
(primary endpoint) was greater with regard to statistical sig-
nificance in the bosutinib group, compared with the ima-
tinib group: 47.2 versus 36.9 percent, respectively.10 Deeper
molecular responses were also higher in the bosutinib group
compared to the imatinib group: MR4, 20.7% vs. 12.0%
(P=0.01) and MR4.5, 8.1% vs. 3.3% (P=0.02). Such find-
ings confirm the efficacy of second-generation TKIs and
their ability to induce faster and deeper molecular
responses relative to that observed with imatinib.11
In conclusion, imatinib has indeed changed the land-
scape of CML.  Subsequently developed TKIs, dasatinib,
nilotinib, and bosutinib, are potential alternatives to ima-
tinib as first-line therapy, mainly due to the deeper and
faster molecular responses they induce. In our opinion,
initial treatment with second-generation TKIs should be
offered initially to patients with higher risk of progres-
sion. Alternatively, imatinib could be the initial therapy
for all patients, with the incorporation of early switch to
second-generation TKIs if optimal response is not
achieved at three months.
Cessation of treatment
Until now the recommendation for TKI therapy in
CML was to continue  treatment indefinitely. However,
there are numerous justifiable reasons for stopping TKI
therapy. Off-target effects of TKIs and severe adverse
drug reactions have been increasingly reported. These
side effects may not only impair the quality of life, but
some of them, such as pulmonary arterial hypertension,
pleural effusion, or vascular occlusive events may poten-
tially modify life expectancy.  In addition, it is forbidden
to administer TKIs to pregnant women, and experience in
pediatric CML cases reveals growth disruption resulting
from TKI therapy. The patients’ requests are also impor-
tant; the question of whether TKI therapy is necessary
lifelong is frequently asked.
Clinical trials have demonstrated the feasibility of stop-
ping TKIs in patients with durable and deep MR beyond
MMR.12-15 The convincing results of all of these studies
have validated the concept of TFR, which has increasing-
ly  become the main focus of clinical trials in CML.16 The
sine qua non condition for proposing TKI cessation is the
achievement of a sustained DMR. A certified laboratory
is necessary to perform and validate the robust molecular
monitoring needed for safety during TFR studies. Great
reassurance is to be found in the reproducibility of TFR
studies over time, and with the adaption of more prag-
matic and applicable criteria for patient consideration.17
Half of the patients who are eligible for TKI discontin-
uation remain treatment-free, while the other 50% recov-
er optimal response upon therapy re-introduction. Most
of the molecular recurrence occurs in the first six months
following TKI cessation. One cannot overstate the impor-
tance of the safety observed to date in TFR trials, evi-
denced by preserved TKI sensitivity and prompt re-induc-
tion of molecular response in patients rechallenged after
molecular recurrence. Of interest is a peculiar transitory
TKI withdrawal syndrome reported in a minority of
patients; the mechanism is unknown.18 A key question
emerging from the experience with TFR trials relates to
the evidence of persisting leukemic cells (e.g., persistent
BCR-ABL detection) without exhibiting true relapse, and
how this status should be defined (functional cure?).
The number of patients who are stopping TKI treat-
ment is increasing over time and it may be possible to re-
attempt TKI cessation more than once in the same
patient. Encouraging results have emerged from a multi-
center study entitled RE-STI, where eligible patients, i.e.,
those with a second sustained DMR, remained in TFR in
one third of cases.19
Although extensive long-term experience is limited,
substantial knowledge accumulated during the last years
justifies moving TFR strategies from research to clinical
practice.
The future of CML
The future of CML therapy must answer those ques-
tions pending from the torrid pace of advance over the
last 20 years. While treatment choices are many, selecting
the safest and optimal path to cure still needs perfection.
One point oft forgotten is the longitudinal cost of TKI
therapy in varying health care systems; with movement
from indefinite to, ideally, defined duration therapy, this
debate will evolve. Continued development of more pre-
cise prognostic information derived at diagnosis, such as
BCR-ABL fusion type,20 the role of cytogenetic abnormal-
ities aside from the Ph chromosome,21 and the formula-
tion of an idealized risk score best able to predict out-
come, including that of survival,22 is ongoing. It is possible
that a more meticulous scrutiny of early response and a
more individualized assessment of response will better
aid decision making regarding any need for change in
treatment.  Particular attention must be paid to comorbid
conditions, especially cardiovascular disease, both at
diagnosis and with therapy change, given the available
data on the increase in risk and impact of comorbidities
on outcome.23
During therapy, the past had us focus on the quantita-
tion of BCR-ABL ‘burden’ by conventional means (cyto-
genetic) whereas the present is sharply focused on the
molecular assessment of disease burden. Such assessment
increasingly utilizes next-generation sequencing, allow-
ing for increased sensitivity, clarity regarding ABL kinase
domain mutations, and clonal hierarchy. This technique
may open the door to a broader consideration of molecu-
lar changes during the course of CML, including the
impact of non-BCR-ABL clonal markers and clonal
hematopoiesis on CML and other comorbid condition
risks. 
Therapy should continue to evolve, with advances
including non-ATP site allosteric inhibitors with ABL001
(asciminib) showing great promise in single-agent phase I
data,24 bolstered by its ability to be safely combined with
available TKIs for potential synergy. In addition, later
generation ABL kinase inhibitors have also moved into
early clinical development, including two agents with
expected activity against the T315I mutation, namely
PF114 (Fusion Pharma) and K0706 (Sun Pharma Advanced
Research Company [SPARC]). Unmet needs continue to
consist of the treatment of advanced phase disease, with
novel options emerging for lymphoid transformation, and
more needed for myeloid blast phase.  In addition, partic-
ular focus is being concentrated on novel agents able to
either deepen suboptimal molecular response to TKIs or
facilitate a second TFR. 
While the future is very bright for those diagnosed with
CML, risks remain, and success requires informed choice,
careful navigation of adverse events and response mile-
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stones, prompt recognition of progressive disease, contin-
ued utilization of allografting in the proper settings, and
prudent and timely selection of candidates for treatment
cessation. 
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